What is the appropriate evaluation and management for a 36‑week pregnant woman presenting with fever?

Evaluation and Management of Fever at 36 Weeks Gestation

A pregnant woman at 36 weeks with fever requires immediate evaluation for intraamniotic infection (chorioamnionitis) and sepsis, with prompt initiation of broad-spectrum antibiotics if infection is suspected, while simultaneously considering important differential diagnoses including pulmonary embolism, pyelonephritis, and viral infections. 1

Initial Assessment and Diagnostic Approach

Temperature Confirmation and Vital Signs

• Confirm fever ≥38°C (100.4°F) as this threshold drives clinical decision-making for both mother and offspring 2
• Measure temperature again at presentation, as only 45% of patients reporting fever have it confirmed on arrival 3
• Assess for maternal tachycardia (>100 bpm), fetal tachycardia (>160 bpm), and uterine tenderness—key signs of intraamniotic infection 1
• Check blood pressure and mean arterial pressure (MAP), as persistent hypotension (MAP <65 mmHg) indicates need for higher level of care 1

Critical Differential Diagnoses to Exclude

Do not assume all fever is infection—consider these life-threatening alternatives first: 1

• Pulmonary embolism: Pregnancy increases VTE risk, and COVID-19 era has heightened awareness of thrombotic complications 1
• Sepsis from non-obstetric sources: Pyelonephritis (11% of pregnancy fevers), particularly important given physiologic urinary stasis 3
• Severe infections: Dengue (24.3%), hepatitis E (14.4%), and tuberculosis carry high maternal mortality 4

Laboratory Evaluation

Obtain immediately: 1

• Complete blood count with differential and platelet count
• Blood cultures before antibiotics
• Lactate level: ≥4 mmol/L indicates need for ICU-level care 1
• Coagulation studies (PT, aPTT, fibrinogen, D-dimer): Pregnancy with COVID-19 can present with hypofibrinolytic DIC and low fibrinogen, unlike typical thrombotic DIC 1
• Urinalysis and urine culture
• Chest radiograph if respiratory symptoms present—do not delay imaging due to radiation concerns 1

Management Based on Clinical Presentation

If Intraamniotic Infection Suspected (Chorioamnionitis)

Clinical diagnosis requires maternal fever ≥38°C PLUS one or more of: 1

• Maternal tachycardia
• Fetal tachycardia
• Purulent cervical discharge
• Uterine tenderness

Do not delay treatment waiting for fever >39°C or additional criteria—maternal fever ≥38°C with any supporting sign warrants action. 1, 2

Antibiotic Regimen

Start immediately with broad-spectrum coverage: 1

• Ampicillin 2g IV every 4-6 hours PLUS
• Gentamicin 5 mg/kg IV every 24 hours (weight-adjusted dosing critical—only 8.8% received correct dosing pre-protocol implementation) 5
• Consider adding clindamycin 900 mg IV every 8 hours for anaerobic coverage if cesarean delivery likely 1

Penicillin-allergic patients:

• No history of anaphylaxis: Cefazolin 2g IV initial, then 1g every 8 hours 1
• History of anaphylaxis/angioedema: Vancomycin 1g IV every 12 hours 1

Delivery Timing

• Intraamniotic infection is NOT an indication for immediate cesarean delivery 6
• Expedite vaginal delivery with oxytocin augmentation if needed 6
• Cesarean only for standard obstetric indications 6
• Prepare for increased postpartum hemorrhage risk (2-3 fold increase)—have uterotonics immediately available 6

If Sepsis Without Clear Intraamniotic Infection

Transfer criteria to ICU/higher level care: 1

• Persistent hypotension (MAP <65 mmHg)
• Need for vasopressors
• Persistent hypoxia (SpO₂ <92% on room air)
• Altered mental status
• Lactate ≥4 mmol/L
• Shock index abnormalities

Antibiotic coverage must be broader: 1

• Ampicillin 2g IV every 4-6 hours (covers GBS, Listeria, Enterococcus)
• Gentamicin or tobramycin (Gram-negative coverage)
• Consider vancomycin if MRSA risk or severe sepsis
• Antibiotics should be given guided by culture and sensitivity results 1

If Stable with Fever of Unknown Source

Common etiologies at this gestational age: 3

• Viral infections (37% of cases): influenza, common cold viruses 3
• Influenza specifically (21%) 3
• Pyelonephritis (11%) 3
• Viral gastroenteritis (6%) 3

Avoid empiric Listeria coverage (amoxicillin) unless specific risk factors present—59% of patients received unnecessary presumptive Listeria treatment when etiology was likely viral 3

Fetal Monitoring Considerations

Continuous Electronic Fetal Monitoring

• Mandatory during maternal fever to assess both fetal well-being and maternal end-organ perfusion 1
• Fetal heart rate tracing provides real-time measure of maternal hemodynamic status 1
• Non-reassuring tracings often improve with maternal stabilization—expectant management appropriate during initial resuscitation 1

Maternal Positioning

• Lateral decubitus position (left or right) to optimize uterine blood flow and maternal hemodynamics 1
• Particularly important beyond 20 weeks gestation 1

Additional Critical Management Points

Temperature Control

• Acetaminophen may not be effective in reducing maternal temperature in true infection 6
• Maternal fever >39°C increases neonatal encephalopathy risk (4.4% vs 1.1% with 38-39°C) 6

VTE Prophylaxis

• Low-molecular-weight heparin prophylaxis for all hospitalized pregnant patients unless contraindications (active bleeding, platelets <25×10⁹/L) 1
• Pregnancy plus sepsis creates extremely high VTE risk (up to 37% in septic patients) 1
• Unfractionated heparin acceptable if imminent delivery 1

Glucose Management

• Initiate insulin for glucose >180 mg/dL 1
• Target range 140-180 mg/dL 1
• Maternal hyperglycemia causes fetal hyperglycemia, acidosis, and decreased uterine blood flow 1

Avoid Common Pitfalls

• Do not delay antibiotics for amniocentesis results if clinical chorioamnionitis suspected 1
• Do not assume absence of fever rules out infection—some intraamniotic infections present without initial fever 1
• Do not perform cesarean delivery solely to "rescue" fetus from fever exposure—no evidence this improves neonatal outcomes 6
• Do not use methylergonovine for postpartum hemorrhage—causes vasoconstriction and hypertension (>10% risk) 1